DOJ lawsuit charges Regeneron with inflating Medicare costs

New York-based Regeneron Pharmaceuticals, manufacturer and seller of the macular degeneration drug Eylea, is being sued by the Department of Justice (DOJ) for allegedly flouting Medicare’s price reporting requirements.

Regeneron failed to report applicable price concessions in the form of credit card processing fees to the Centers for Medicare and Medicaid Services (CMS), the DOJ claimed in a press release Wednesday.

The lawsuit was originally filed under the qui tam provisions of the False Claims Act by two former Regeneron employees. The United States intervened in the case, which is permitted under the act. If found liable, Regeneron could pay treble damages, plus penalties.